This recent article in the Sunday Times discusses how an extract of magic mushrooms may be able to make significant improvements in the treatment of severe depression.
We were delighted to bring ApconiX’s drug project toxicologist expertise to the team of experts working with COMPASS Pathways to find a safe, efficient and effective route into clinical trials.
The 400-patient trial will establish whether psilocybin, the active ingredient in magic mushrooms, can help patients where other treatments have failed.
COMPASS Pathways is a life sciences company dedicated to accelerating patient access to evidence-based innovation in mental health. We are proud to support them in this mission.